Cargando…

Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications

BACKGROUND: This study was conducted to determine the prevalence of metabolic syndrome (Mets) in schizophrenic patients in a 6-month period of treatment with antipsychotic medications. METHODS: In this study, 60 volunteer schizophrenic patients were included. At the onset and 6 months after treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaberi, Nayyer, Faramarzi, Elnaz, Farahbakhsh, Mostafa, Ostadarahimi, Alireza, Asghari Jafarabadi, Mohammad, Fakhari, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Babol University of Medical Sciences 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442470/
https://www.ncbi.nlm.nih.gov/pubmed/32874439
http://dx.doi.org/10.22088/cjim.11.3.310
_version_ 1783573461551022080
author Jaberi, Nayyer
Faramarzi, Elnaz
Farahbakhsh, Mostafa
Ostadarahimi, Alireza
Asghari Jafarabadi, Mohammad
Fakhari, Ali
author_facet Jaberi, Nayyer
Faramarzi, Elnaz
Farahbakhsh, Mostafa
Ostadarahimi, Alireza
Asghari Jafarabadi, Mohammad
Fakhari, Ali
author_sort Jaberi, Nayyer
collection PubMed
description BACKGROUND: This study was conducted to determine the prevalence of metabolic syndrome (Mets) in schizophrenic patients in a 6-month period of treatment with antipsychotic medications. METHODS: In this study, 60 volunteer schizophrenic patients were included. At the onset and 6 months after treatment with antipsychotic medications, fasting blood sugar (FBS), serum triglyceride (TG), high density lipoprotein (HDL), weight, waist circumference (WC), and blood pressure were determined. We defined Mets according to ATPIII criteria. RESULTS: After a 6-month treatment with antipsychotic drugs, the mean WC, serum TG, HDL, systolic and diastolic blood pressure increased but the changes of WC and HDL were statistically significant (p<0.05). We found that the percentage of patients with high WC, low HDL levels, and Mets increased after treatment which was statistically significant (p<0.05). CONCLUSION: It is recommended that nutritional and lifestyle changes intervention should be implanted for schizophrenic patients undergoing treatment.
format Online
Article
Text
id pubmed-7442470
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Babol University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-74424702020-08-31 Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications Jaberi, Nayyer Faramarzi, Elnaz Farahbakhsh, Mostafa Ostadarahimi, Alireza Asghari Jafarabadi, Mohammad Fakhari, Ali Caspian J Intern Med Original Article BACKGROUND: This study was conducted to determine the prevalence of metabolic syndrome (Mets) in schizophrenic patients in a 6-month period of treatment with antipsychotic medications. METHODS: In this study, 60 volunteer schizophrenic patients were included. At the onset and 6 months after treatment with antipsychotic medications, fasting blood sugar (FBS), serum triglyceride (TG), high density lipoprotein (HDL), weight, waist circumference (WC), and blood pressure were determined. We defined Mets according to ATPIII criteria. RESULTS: After a 6-month treatment with antipsychotic drugs, the mean WC, serum TG, HDL, systolic and diastolic blood pressure increased but the changes of WC and HDL were statistically significant (p<0.05). We found that the percentage of patients with high WC, low HDL levels, and Mets increased after treatment which was statistically significant (p<0.05). CONCLUSION: It is recommended that nutritional and lifestyle changes intervention should be implanted for schizophrenic patients undergoing treatment. Babol University of Medical Sciences 2020-05 /pmc/articles/PMC7442470/ /pubmed/32874439 http://dx.doi.org/10.22088/cjim.11.3.310 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jaberi, Nayyer
Faramarzi, Elnaz
Farahbakhsh, Mostafa
Ostadarahimi, Alireza
Asghari Jafarabadi, Mohammad
Fakhari, Ali
Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
title Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
title_full Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
title_fullStr Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
title_full_unstemmed Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
title_short Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
title_sort prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442470/
https://www.ncbi.nlm.nih.gov/pubmed/32874439
http://dx.doi.org/10.22088/cjim.11.3.310
work_keys_str_mv AT jaberinayyer prevalenceofmetabolicsyndromeinschizophreniapatientstreatedwithantipsychoticmedications
AT faramarzielnaz prevalenceofmetabolicsyndromeinschizophreniapatientstreatedwithantipsychoticmedications
AT farahbakhshmostafa prevalenceofmetabolicsyndromeinschizophreniapatientstreatedwithantipsychoticmedications
AT ostadarahimialireza prevalenceofmetabolicsyndromeinschizophreniapatientstreatedwithantipsychoticmedications
AT asgharijafarabadimohammad prevalenceofmetabolicsyndromeinschizophreniapatientstreatedwithantipsychoticmedications
AT fakhariali prevalenceofmetabolicsyndromeinschizophreniapatientstreatedwithantipsychoticmedications